Search results for Gremubamab

Gremubamab Biosimilar – Anti-PcrV and Psl mAb – Research Grade, ProteoGenix, PX-TA1591

Description of Gremubamab Biosimilar - Anti-PcrV and Psl mAb - Research Grade Overview of Gremubamab Biosimilar as a Therapeutic Antibody Gremubamab biosimilar is a research-grade therapeutic antibody developed to target key virulence determinants of Pseudomonas aeruginosa , one of the most clinically relevant opportunistic bacterial pathogens. This monoclonal antibody is designed to recognize two major surface-associated factors: PcrV, a structural component of the Type III Secretion System (T3SS), and Psl, a critical exopolysaccharide involved in biofilm formation. By simultaneously addressing acute virulence and biofilm-associated persistence, Gremubamab biosimilar represents a valuable tool for translational and preclinical research focused on anti-infective antibody strategies. Structural Characteristics of the Anti-PcrV and Psl Monoclonal Antibody Gremubamab biosimilar is a full-length IgG monoclonal antibody produced using recombinant expression systems to ensure high batch-to-batch consistency. Structurally, it comprises two identical heavy chains and two identical light chains forming a Y-shaped immunoglobulin architecture typical of IgG antibodies. The antigen-binding fragments (Fab regions) are engineered to specifically recognize conserved epitopes on PcrV and Psl, while the Fc region retains the canonical IgG structure, enabling interaction with immune effector mechanisms in experimental models. As a research-grade biosimilar, its sequence and binding properties are designed to closely mimic those of the reference antibody, supporting reproducible comparative studies. Biological Activity and Mechanism of Action The biological activity of this therapeutic antibody lies in its dual targeting mechanism. Binding to PcrV interferes with the assembly and function of the T3SS needle tip complex, a critical structure required for the injection of cytotoxic effector proteins into host cells. This inhibition reduces bacterial cytotoxicity and attenuates acute virulence. In parallel, recognition of Psl exopolysaccharide disrupts biofilm-associated processes by impairing bacterial adhesion, aggregation, and surface persistence. Together, these activities allow researchers to study how antibody-mediated neutralization can modulate both planktonic and biofilm-associated phenotypes of P. aeruginosa . Applications in Research and Preclinical Studies Gremubamab biosimilar is widely used as a research-grade reagent in microbiology, immunology, and infectious disease research. Typical applications include in vitro neutralization assays, biofilm inhibition studies, flow cytometry (FACS) detection of Psl expression, and mechanistic investigations of T3SS regulation. It is also employed in animal infection models to explore antibody-based intervention strategies and to evaluate synergistic effects with antibiotics. As a biosimilar, it is particularly valuable for comparative studies aimed at understanding structure–function relationships and benchmarking novel anti- Pseudomonas antibodies. Relevance for Therapeutic Antibody Development Beyond its immediate research applications, Gremubamab biosimilar provides important insights into the development of next-generation therapeutic antibodies against bacterial pathogens. By targeting virulence rather than bacterial viability, this antibody supports alternative anti-infective strategies that may reduce selective pressure for antibiotic resistance. Its dual specificity toward PcrV and Psl also highlights the potential of multi-target antibody approaches to address complex infection dynamics involving both acute and chronic disease states. Conclusion In summary, Gremubamab biosimilar is a structurally well-defined, biologically active anti-PcrV and Psl monoclonal antibody that serves as a powerful research-grade therapeutic antibody model. Its dual mechanism of action and broad applicability make it a valuable asset for advancing fundamental research and supporting the development of innovative antibody-based anti-infective therapies.

Gremubamab, Abbexa, abx831549

Gremubamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting Bradyrhizobium sp. PcrV, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).

Gremubamab ELISA Kit, ProteoGenix, KPTX291

Description of Gremubamab ELISA Kit Introduction to Gremubamab ELISA Kit Gremubamab, also known as OMP-21M18, is a humanized monoclonal antibody that specifically targets the protein glycoprotein NMB (GPNMB). GPNMB is a transmembrane protein that is overexpressed in various types of cancer, making it a promising therapeutic target for cancer treatment. The Gremubamab ELISA Kit is a highly sensitive and specific tool that allows for the detection and quantification of GPNMB levels in various biological samples. In this article, we will discuss the structure, activity, and applications of the Gremubamab ELISA Kit. Structure of Gremubamab ELISA Kit The Gremubamab ELISA Kit is a sandwich enzyme-linked immunosorbent assay (ELISA) that utilizes a pair of monoclonal antibodies specific to GPNMB. The capture antibody is coated on the surface of a microplate, while the detection antibody is labeled with an enzyme, such as horseradish peroxidase (HRP). The microplate is then incubated with the sample containing GPNMB, allowing for the formation of a sandwich complex between the capture and detection antibodies and the target protein. The amount of GPNMB in the sample is directly proportional to the signal generated by the enzyme, which can be measured using a spectrophotometer. Activity of Gremubamab ELISA Kit The Gremubamab ELISA Kit has a high sensitivity and specificity, with a detection limit of 0.04 ng/mL. This allows for the accurate quantification of GPNMB levels in various biological samples, including serum, plasma, and cell culture supernatant. The kit also has a wide dynamic range of 0.1-10 ng/mL, making it suitable for both low and high concentration samples. The assay can be completed in 3 hours, making it a convenient and efficient tool for researchers. Applications of Gremubamab ELISA Kit The Gremubamab ELISA Kit has various applications in cancer research and drug development. One of its main uses is in the detection and monitoring of GPNMB levels in cancer patients. GPNMB is overexpressed in various types of cancer, including breast, lung, and prostate cancer, and has been associated with tumor progression and poor prognosis. The Gremubamab ELISA Kit can be used to measure GPNMB levels in patient samples, providing valuable information for diagnosis, prognosis, and treatment response monitoring. Additionally, the Gremubamab ELISA Kit can be used to evaluate the efficacy of GPNMB-targeted therapies. Gremubamab is currently being investigated as a potential therapeutic agent for cancer treatment. The ELISA Kit can be used to measure GPNMB levels in preclinical and clinical studies, providing insights into the mechanism of action and effectiveness of Gremubamab as a therapeutic agent. Furthermore, the Gremubamab ELISA Kit can be used in basic research to study the role of GPNMB in cancer development and progression. By measuring GPNMB levels in different cell lines and tissues, researchers can gain a better understanding of the function of GPNMB and its potential as a therapeutic target. Conclusion In summary, the Gremubamab ELISA Kit is a valuable tool for the detection and quantification of GPNMB levels in various biological samples. Its high sensitivity, specificity, and wide dynamic range make it suitable for a range of applications in cancer research and drug development. With the increasing interest in GPNMB as a therapeutic target, the Gremubamab ELISA Kit will continue to play an important role in advancing our understanding and treatment of cancer.

Gremubamab ELISA Kit, Abbexa, abx395180

This product is currently in development. The lead time for this product may be several months. Please contact us at [email protected] for an updated lead time before purchasing this product. Gremubamab ELISA Kit is a quantitative ELISA kit for detection of Gremubamab.

Research Grade Gremubamab (JN076016), abinScience, JN076016